Antineoplastics
1
Reactions 1418 - 8 Sep 2012 Antineoplastics Fatigue and loss of appetite in an elderly patient: case report A 79-year-old man developed fatigue and loss of appetite during treatment the antineoplastics gimeracil/oteracil/ tegafur and tegafur/uracil [routes and frequencies not stated]. The man, who had a history of advanced gastric cancer, a total gastrectomy, a splenectomy and a second regional lymph node dissection, developed invasion to the diaphragm and lymph node metastasis. He was administered a 1-week regimen of gimeracil/oteracil/ tegafur 80 mg/m 2 for postoperative adjuvant chemotherapy. He developed intense general fatigue [time to reaction onset not clearly stated], so his gimeracil/ oteracil/tegafur dose was reduced to 80 mg/body and administered for 2 weeks. His fatigue worsened, and he also developed a loss of appetite. The patient refused the drug, and gimeracil/oteracil/ tegafur was withdrawn. Subsequently, he developed ascites due to peritoneal dissemination of gastric cancer. Tegafur/uracil was started at 1.5 g/body (tegafur 300 mg/ body) for a 6-week period, and paclitaxel was given on day 28. After a 3-week drug break, tegafur/uracil 1.5 g/body was given for a 4-week period. Paclitaxel was administered on day 1. His ascites improved. Thereafter, a decline in appetite and general fatigue developed [time to reaction onset not clearly stated]. Therefore, tegafur/uracil was suspended. At last follow-up, he had no signs of peritoneal recurrence. [Outcome of ADRs not stated.] Author comment: The patient developed a loss of appetite and fatigue caused by gimeracil/oteracil/tegafur. He also experienced a decline in appetite and general fatigue with tegafur/uracil. Okumura K, et al. Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel. Gan to Kagaku Ryoho 39: 667-670, No. 4, Apr 2012 [Japanese; summarised from a translation] - Japan 803076627 » Editorial comment: This paper included a second patient who received gimeracil/oteracil/tegafur, but no adverse reactions associated with gimeracil/oteracil/tegafur were reported in this patient. 1 Reactions 8 Sep 2012 No. 1418 0114-9954/10/1418-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1418 - 8 Sep 2012
Antineoplastics
Fatigue and loss of appetite in an elderly patient:case report
A 79-year-old man developed fatigue and loss of appetiteduring treatment the antineoplastics gimeracil/oteracil/tegafur and tegafur/uracil [routes and frequencies notstated].
The man, who had a history of advanced gastric cancer, atotal gastrectomy, a splenectomy and a second regionallymph node dissection, developed invasion to thediaphragm and lymph node metastasis. He wasadministered a 1-week regimen of gimeracil/oteracil/tegafur 80 mg/m2 for postoperative adjuvantchemotherapy. He developed intense general fatigue [timeto reaction onset not clearly stated], so his gimeracil/oteracil/tegafur dose was reduced to 80 mg/body andadministered for 2 weeks. His fatigue worsened, and healso developed a loss of appetite.
The patient refused the drug, and gimeracil/oteracil/tegafur was withdrawn. Subsequently, he developedascites due to peritoneal dissemination of gastric cancer.Tegafur/uracil was started at 1.5 g/body (tegafur 300 mg/body) for a 6-week period, and paclitaxel was given onday 28. After a 3-week drug break, tegafur/uracil 1.5 g/bodywas given for a 4-week period. Paclitaxel was administeredon day 1. His ascites improved. Thereafter, a decline inappetite and general fatigue developed [time to reactiononset not clearly stated]. Therefore, tegafur/uracil wassuspended. At last follow-up, he had no signs of peritonealrecurrence. [Outcome of ADRs not stated.]
Author comment: The patient developed a loss ofappetite and fatigue caused by gimeracil/oteracil/tegafur. Healso experienced a decline in appetite and general fatiguewith tegafur/uracil.Okumura K, et al. Two cases of advanced gastric cancer with peritonitiscarcinomatosa that showed disappearance of ascites and obtained a good quality oflife by using DIF and paclitaxel. Gan to Kagaku Ryoho 39: 667-670, No. 4, Apr2012 [Japanese; summarised from a translation] - Japan 803076627
» Editorial comment: This paper included a second patientwho received gimeracil/oteracil/tegafur, but no adversereactions associated with gimeracil/oteracil/tegafur werereported in this patient.
1
Reactions 8 Sep 2012 No. 14180114-9954/10/1418-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
